BREAST CANCER

The FDA approves pertuzumab-dpzb as the first interchangeable biosimilar for HER2-positive breast cancer, enhancing treatment options and accessibility.

A coclinical trial reveals a promising triplet therapy for advanced HR+ breast cancer, highlighting the importance of genetic profiling in treatment efficacy.

A recent study reveals survival trends in metastatic breast cancer, highlighting subtype-specific treatment needs and improved outcomes for HER2-positive patients.

Study data reveal key risk factors for pneumonitis in patients with metastatic breast cancer treated with T-DXd, highlighting the need for proactive management strategies.

New trial results reveal sacituzumab govitecan shows promise for HR+/HER2– metastatic breast cancer, despite missing primary survival goals.

Camizestrant shows promising antitumor activity and tolerability when combined with CDK4/6 inhibitors in patients with advanced ER+, HER2– breast cancer.

During a live event, Sara Nunnery, MD, MSCI, and participants discussed impressions of recent data from the ASCENT-04 and ASCENT-03 trials.

Combination therapy with sacituzumab govitecan and pembrolizumab enhances quality of life and delays physical decline in metastatic triple-negative breast cancer patients.

New findings reveal significant PFS benefits of T-DXd plus pertuzumab over traditional therapies for HER2-positive advanced breast cancer patients.

Datopotamab deruxtecan significantly enhances survival rates in first-line treatment for metastatic triple-negative breast cancer, offering new hope for patients.

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

Sacituzumab govitecan significantly improves progression-free survival in advanced triple-negative breast cancer, offering a promising alternative to chemotherapy.

Gedatolisib enhances progression-free survival in advanced breast cancer patients, showcasing significant benefits when combined with fulvestrant and palbociclib.

New trial data reveals T-DXd plus THP significantly improves pathologic complete response rates in high-risk HER2-positive early breast cancer patients.

Sacituzumab tirumotecan significantly improves progression-free survival in HR+/HER2– breast cancer compared with traditional chemotherapy.

New trial data reveals T-DXd significantly improves disease-free survival in high-risk HER2-positive breast cancer patients compared to T-DM1, offering hope for better outcomes.

Giredestrant combined with everolimus significantly enhances progression-free survival in advanced ER-positive breast cancer, offering a promising new treatment option.

Ribociclib combined with aromatase inhibitors significantly enhances invasive disease-free survival in early breast cancer, offering lasting benefits beyond treatment.

Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone.

Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a pivotal phase 3 trial.

During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic breast cancer.

Datopotamab deruxtecan has shown significant survival benefits in patients with metastatic triple-negative breast cancer, marking a potential breakthrough in therapy options.

During a live event, Claudine Isaacs, MD, and participants discuss using elacestrant or T-DXd after progression in ESR1-mutated metastatic breast cancer.

FDA fast tracks ETX-636, a promising treatment for advanced breast cancer with PIK3CA mutations, aiming to improve patient outcomes.

FDA accepts T-DXd for neoadjuvant HER2-positive breast cancer treatment, promising improved outcomes and safety for high-risk patients.